139 related articles for article (PubMed ID: 2179640)
1. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
[TBL] [Abstract][Full Text] [Related]
2. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1997 Dec; 11 Suppl 5():S15-21. PubMed ID: 9436933
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and cerebrospinal fluid penetration of daunorubicin, idarubicin, and their metabolites in the nonhuman primate model.
Berg SL; Reid J; Godwin K; Murry DJ; Poplack DG; Balis FM; Ames MM
J Pediatr Hematol Oncol; 1999; 21(1):26-30. PubMed ID: 10029808
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
[TBL] [Abstract][Full Text] [Related]
5. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
6. Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve.
Schleyer E; Kühn S; Rührs H; Unterhalt M; Kaufmann CC; Kern W; Braess J; Sträubel G; Hiddemann W
Leukemia; 1996 Apr; 10(4):707-12. PubMed ID: 8618451
[TBL] [Abstract][Full Text] [Related]
7. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Tidefelt U; Sundman-Engberg B; Paul C
Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects.
Elbaek K; Ebbehøj E; Jakobsen A; Juul P; Rasmussen SN; Bastholt L; Dalmark M; Steiness E
Clin Pharmacol Ther; 1989 Jun; 45(6):627-34. PubMed ID: 2731405
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of intravenous and oral idarubicin in cancer patients.
Tamassia V; Pacciarini MA; Moro E; Piazza E; Vago G; Libretti A
Int J Clin Pharmacol Res; 1987; 7(5):419-26. PubMed ID: 3478310
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and tissue distribution of idarubicin and its active metabolite idarubicinol in the rabbit.
Looby M; Linke R; Weiss M
Cancer Chemother Pharmacol; 1997; 39(6):554-6. PubMed ID: 9118470
[TBL] [Abstract][Full Text] [Related]
13. Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course.
Eksborg S; Björkholm M; Hast R; Fagerlund E
Anticancer Drugs; 1997 Jan; 8(1):42-7. PubMed ID: 9147610
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of idarubicin.
Robert J
Clin Pharmacokinet; 1993 Apr; 24(4):275-88. PubMed ID: 8491056
[TBL] [Abstract][Full Text] [Related]
15. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
17. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability and pharmacology of oral idarubicin.
Stewart DJ; Grewaal D; Green RM; Verma S; Maroun JA; Redmond D; Robillard L; Gupta S
Cancer Chemother Pharmacol; 1991; 27(4):308-14. PubMed ID: 1998987
[TBL] [Abstract][Full Text] [Related]
19. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients.
Zanette L; Zucchetti M; Freshi A; Erranti D; Tirelli U; D'Incalci M
Cancer Chemother Pharmacol; 1990; 25(6):445-8. PubMed ID: 2311174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]